Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride

Cat. No.: HY-122710A

CAS No.: 2245697-85-0

Molecular Formula: $C_{25}H_{35}ClN_4O_{10}$

Molecular Weight: 587.02

Target: E3 Ligase Ligand-Linker Conjugates

Pathway: PROTAC

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (85.18 mM; Need ultrasonic)

Preparing Stock Solutions	Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
	1 mM	1.7035 mL	8.5176 mL	17.0352 mL
	5 mM	0.3407 mL	1.7035 mL	3.4070 mL
	10 mM	0.1704 mL	0.8518 mL	1.7035 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1].

IC_{50} & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. James Bradner, et al. Methods to induce targeted protein degradation through bifunctional molecules. WO2016105518A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA